NEW YORK, August 16, 2016 /PRNewswire/ --
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
Wilmington, Delaware headquartered Incyte Corp.'s stock finished Monday's session at $80.55, which was a slight decline of 0.62%. A total volume of 988,389 shares was traded. Over the previous three months, the Company's shares have gained 5.34%. The stock is trading below its 50-day moving average by 3.32%. Moreover, shares of Incyte, which focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the US and internationally, have a Relative Strength Index (RSI) of 37.95.
On August 9th, 2016, Incyte reported that total revenues for the quarter ended June 30, 2016 were $246.29 million as compared to $162.98 million for the same period in 2015, representing a 51% growth. The company's net income for the quarter ended June 30, 2016 was $34 million, or $0.18 per basic and diluted share, as compared to net income of $9 million, or $0.05 per basic and diluted share for the same period in 2015.
On August 10th, 2016, research firm Leerink Partners reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $85 a share to $95 a share. Visit us today and access our complete research report on INCY at:
BioDelivery Sciences Intl.
Shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. ended yesterday's session 2.13% higher at $2.88 with a total volume of 921,653 shares traded. The stock has gained 9.92% in the past one month and 41.18% in the previous three months. The Company's shares are trading 16.62% above their 50-day moving average. Moreover, shares of BioDelivery Sciences International, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 66.25.
On August 9th, 2016, BioDelivery Sciences reported that total net revenue for the three-months ended June 30th, 2016, was $5.0 million, an increase of 189% over last year's corresponding quarter. The company noted that net loss for Q2 ended June 30th, 2016, was $16.5 million, or ($0.31) per diluted share, compared to a net loss of $19.2 million, or ($0.37) per diluted share, in the same period of 2015. The complimentary report on BDSI can be downloaded at:
On Monday, Rockville, Maryland headquartered Synthetic Biologics Inc.'s stock closed the day flat at $1.72. A total volume of 296,738 shares was traded. The Company's shares have advanced 1.18% in the last one month. The stock is trading 3.20% below its 50-day moving average. Additionally, shares of Synthetic Biologics, which engages in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases in the US, have an RSI of 48.95.
On August 3rd, 2016, Synthetic Biologics reported that net loss for Q2 2016 was $5.68 million, or ($0.10) per diluted share, compared to a net loss of $13.62 million, or ($0.19) per diluted share, in the same period of 2015. The company noted that research and development expenses declined by 5% to $7.2 million for Q2 2016, from $7.5 million for Q2 2015. Register for free on Stock-Callers.com and access the latest research report on SYN at:
Shares in Novato, California headquartered Raptor Pharmaceuticals Corp. ended the day 0.15% higher at $6.79. A total volume of 759,656 shares was traded, which was above their three months average volume of 592,390 shares. The stock has gained 12.79% in the last one month, 44.47% in the previous three months, and 30.58% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 17.04% and 33.45%, respectively. Furthermore, shares of Raptor Pharmaceuticals, which focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, have an RSI of 64.26.
On August 4th, 2016, Raptor Pharmaceuticals reported global net product revenue of $32.0 million for Q2 2016, a 37.3% increase compared to $23.3 million for the same period in 2015. The company reported GAAP net loss of $14.0 million, or $0.16 per share, for Q2 2016 compared to a GAAP net loss of $13.9 million, or $0.17 per share, for the same period in 2015. Get free access to your research report on RPTP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA